Published in Br J Pharmacol on June 01, 2001
Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications. Eur J Pharmacol (2011) 1.01
Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond) (2010) 0.96
Effect of Treatment of Sprague Dawley Rats with AVE7688, Enalapril, or Candoxatril on Diet-Induced Obesity. J Obes (2010) 0.89
Vascular and neural dysfunctions in obese Zucker rats: effect of AVE7688. Exp Diabetes Res (2009) 0.89
Microvascular responsiveness in obesity: implications for therapeutic intervention. Br J Pharmacol (2012) 0.88
Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice. Neuropharmacology (2010) 0.87
Effect of Inhibition of Angiotensin-Converting Enzyme and/or Neutral Endopeptidase on Neuropathy in High-Fat-Fed C57Bl/6J Mice. J Obes (2012) 0.80
Vasopeptidase inhibitors: will they have a role in clinical practice? Br J Clin Pharmacol (2004) 0.79
Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels. Diabetologia (2016) 0.75
Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev (1992) 4.56
Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol (1988) 3.54
Nitric oxide release is present from incubated skeletal muscle preparations. J Appl Physiol (1985) (1994) 3.02
Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J (1989) 2.24
Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry (1977) 2.17
Regional and cardiac haemodynamic responses to glyceryl trinitrate, acetylcholine, bradykinin and endothelin-1 in conscious rats: effects of NG-nitro-L-arginine methyl ester. Br J Pharmacol (1990) 1.77
Insulin resistance after hypertension induced by the nitric oxide synthesis inhibitor L-NMMA in rats. Am J Physiol (1995) 1.68
Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am J Physiol (1998) 1.32
Retracted Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes (1997) 1.08
Complete differentiation between enkephalinase and angiotensin-converting enzyme inhibition by retro-thiorphan. Proc Natl Acad Sci U S A (1983) 1.01
Regional haemodynamic effects of captopril, enalaprilat and lisinopril in conscious water-replete and water-deprived Brattleboro rats. Clin Sci (Lond) (1990) 1.00
Glucose transport activity in insulin-resistant rat muscle. Effects of angiotensin-converting enzyme inhibitors and bradykinin antagonism. Diabetes (1996) 0.90
ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide. Am J Physiol (1999) 0.90
Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension (1994) 0.90
Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans. Diabetologia (1994) 0.89
Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). J Hypertens (1999) 0.87
Effects of combined neutral endopeptidase 24-11 and angiotensin-converting enzyme inhibition on femoral vascular conductance in streptozotocin-induced diabetic rats. Br J Pharmacol (2000) 0.87
Insulin sensitivity, clearance and release in kininogen-deficient rats. Exp Physiol (1999) 0.87
Mechanisms of insulin resistance and new pharmacological approaches to metabolism and diabetic complications. Clin Exp Pharmacol Physiol (1998) 0.87
Measurement of glucose concentrations in rats: differences between glucose meter and plasma laboratory results. Diabetologia (1999) 0.86
Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. Diabetes Care (1990) 0.85
Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther (1993) 0.85
Intravascular and interstitial degradation of bradykinin in isolated perfused rat heart. Br J Pharmacol (1997) 0.85
Bradykinin B2 receptors on skeletal muscle are coupled to inositol 1,4,5-trisphosphate formation. Diabetes (1996) 0.84
Kininase II-type enzymes. Their putative role in muscle energy metabolism. Diabetes (1996) 0.84
Effects of the neutral endopeptidase inhibitor, SQ 28,603, on regional haemodynamic responses to atrial natriuretic peptide or proendothelin-1 [1-38] in conscious rats. Br J Pharmacol (1992) 0.84
NO-mediated vasodilation in the rat liver. Role of hepatocytes and liver endothelial cells. J Hepatol (1997) 0.83
Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive DOCA-salt rats. J Cardiovasc Pharmacol (1992) 0.82
Degradation of bradykinin by neutral endopeptidase (EC 3.4.24.11) in cultured human endothelial cells. Eur J Clin Chem Clin Biochem (1993) 0.81
Effect of endopeptidase-24.11 inhibitors and C-ANP receptor ligand on responses evoked in arterioles of rat cremaster muscle by atrial natriuretic peptide. Br J Pharmacol (1995) 0.80
Comparative effects of the dual metallopeptidase inhibitor, MDL 100,240 and of enalaprilat on regional and on cardiac haemodynamics in conscious, hypertensive, transgenic ((mRen-2)27) rats. Br J Pharmacol (1997) 0.80
Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes. J Pharmacol Exp Ther (1998) 0.80
Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J Pharmacol Exp Ther (1995) 0.79
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proc Natl Acad Sci U S A (1994) 0.79
Bradykinin metabolism in rat hind limbs. Shock (1998) 0.79
Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities. J Cardiovasc Pharmacol (1999) 0.77
Angiotensin-converting enzyme inhibitor increases insulin-induced pp185 phosphorylation in liver and muscle of obese rats. Biochem Mol Biol Int (1998) 0.77
Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long-term treatment with enalapril and losartan. Metabolism (1999) 0.77
Bradykinin degrading activity in cultured human endothelial cells. J Cardiovasc Pharmacol (1992) 0.76
Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature (1996) 7.15
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 4.31
Viral RNA annealing activities of human immunodeficiency virus type 1 nucleocapsid protein require only peptide domains outside the zinc fingers. Proc Natl Acad Sci U S A (1992) 3.71
First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses. J Mol Biol (1995) 3.63
The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med (2000) 2.62
Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding. Nature (2000) 2.57
Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev (1993) 2.24
Determination of the structure of the nucleocapsid protein NCp7 from the human immunodeficiency virus type 1 by 1H NMR. EMBO J (1992) 2.21
The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature (1980) 2.13
Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med (2001) 2.07
Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Science (1996) 2.01
Basic amino acids flanking the zinc finger of Moloney murine leukemia virus nucleocapsid protein NCp10 are critical for virus infectivity. J Virol (1993) 1.91
First large scale chemical synthesis of the 72 amino acid HIV-1 nucleocapsid protein NCp7 in an active form. Biochem Biophys Res Commun (1991) 1.88
High-affinity enkephalin-degrading peptidase in brain is increased after morphine. Nature (1978) 1.87
DNA Bifunctional intercalators. 2. Fluorescence properties and DNA binding interaction of an ethidium homodimer and an acridine ethidium heterodimer. Biochemistry (1978) 1.86
Ethidium dimer: a new reagent for the fluorimetric determination of nucleic acids. Anal Biochem (1979) 1.81
Two rotameric forms of open ring 7-methylguanine are present in alkylated polynucleotides. Nucleic Acids Res (1984) 1.74
International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev (1999) 1.74
NCp7 activates HIV-1Lai RNA dimerization by converting a transient loop-loop complex into a stable dimer. J Biol Chem (1996) 1.73
Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature (1997) 1.72
NMR structure of the HIV-1 regulatory protein VPR. J Mol Biol (2003) 1.64
DNA bifunctional intercalators. I. Synthesis and conformational properties of an ethidium homodimer and of an acridine ethidium heterodimer. Biochemistry (1978) 1.51
Conformational behaviour of the active and inactive forms of the nucleocapsid NCp7 of HIV-1 studied by 1H NMR. J Mol Biol (1994) 1.49
Solid phase synthesis of the retroviral nucleocapsid protein NCp10 of Moloney murine leukaemia virus and related "zinc-fingers" in free SH forms. Influence of zinc chelation on structural and biochemical properties. Int J Pept Protein Res (1990) 1.48
Expression of neutral endopeptidase (enkephalinase) in heterologous COS-1 cells. Characterization of the recombinant enzyme and evidence for a glutamic acid residue at the active site. J Biol Chem (1988) 1.40
Nucleic acid sequence discrimination by the HIV-1 nucleocapsid protein NCp7: a fluorescence study. Biochemistry (1999) 1.39
Ordered aggregation of ribonucleic acids by the human immunodeficiency virus type 1 nucleocapsid protein. Biopolymers (1997) 1.39
Human immunodeficiency virus type 1 nucleocapsid protein specifically stimulates Mg2+-dependent DNA integration in vitro. J Virol (1997) 1.37
Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. J Neurosci (1998) 1.35
DNA intercalating compounds as potential antitumor agents. 2. Preparation and properties of 7H-pyridocarbazole dimers. J Med Chem (1980) 1.34
Pre- and postsynaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res (1990) 1.33
The gag precursor contains a specific HIV-1 protease cleavage site between the NC (P7) and P1 proteins. FEBS Lett (1993) 1.27
Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-1. J Biol Chem (1999) 1.27
Conformation of Met5-enkephalin determined by high field PMR spectroscopy. Nature (1976) 1.26
Involvement of HIV-I nucleocapsid protein in the recruitment of reverse transcriptase into nucleoprotein complexes formed in vitro. J Biol Chem (1998) 1.26
Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci U S A (1996) 1.26
Connective tissue in diabetes mellitus: biochemical alterations of the intercellular matrix with special reference to proteoglycans, collagens and basement membranes. Diabete Metab (1985) 1.25
Deltakephalin, Tyr-D-Thr-Gly-Phe-Leu-Thr: a new highly potent and fully specific agonist for opiate delta-receptors. Biochem Biophys Res Commun (1983) 1.23
1H NMR structure and biological studies of the His23-->Cys mutant nucleocapsid protein of HIV-1 indicate that the conformation of the first zinc finger is critical for virus infectivity. Biochemistry (1994) 1.23
NMR structure of the (52-96) C-terminal domain of the HIV-1 regulatory protein Vpr: molecular insights into its biological functions. J Mol Biol (1999) 1.23
Properties and growth mechanism of the ordered aggregation of a model RNA by the HIV-1 nucleocapsid protein: an electron microscopy investigation. Biopolymers (1998) 1.22
High-throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity. Anal Biochem (2001) 1.21
D-Tyr--Ser-Gly--Phe--Leu--Thr, a highly preferential ligand for delta-opiate receptors. FEBS Lett (1980) 1.15
Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation. Eur J Pharmacol (1992) 1.14
Structure of the complex between the HIV-1 nucleocapsid protein NCp7 and the single-stranded pentanucleotide d(ACGCC). J Mol Biol (1998) 1.14
The zinc fingers of HIV nucleocapsid protein NCp7 direct interactions with the viral regulatory protein Vpr. J Biol Chem (1997) 1.14
CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Prog Neurobiol (1999) 1.14
Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors. Neuroscience (2005) 1.14
NMR structure of the N-terminal SH3 domain of GRB2 and its complex with a proline-rich peptide from Sos. Nat Struct Biol (1994) 1.13
The annealing of tRNA3Lys to human immunodeficiency virus type 1 primer binding site is critically dependent on the NCp7 zinc fingers structure. J Biol Chem (1998) 1.11
Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci U S A (1999) 1.11
Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol (1998) 1.10
Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci (2001) 1.08
Identification of glutamic acid 646 as a zinc-coordinating residue in endopeptidase-24.11. J Biol Chem (1991) 1.08
A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity. FASEB J (1999) 1.07
Nociceptin/orphanin FQ metabolism: role of aminopeptidase and endopeptidase 24.15. J Neurochem (1997) 1.07
Primary structure homologies between two zinc metallopeptidases, the neutral endopeptidase 24.11 ("enkephalinase") and thermolysin, through clustering analysis. Biochemistry (1988) 1.07
DNA tris-intercalation: first acridine trimer with DNA affinity in the range of DNA regulatory proteins. Kinetic studies. Biochemistry (1985) 1.07
Two short basic sequences surrounding the zinc finger of nucleocapsid protein NCp10 of Moloney murine leukemia virus are critical for RNA annealing activity. Nucleic Acids Res (1993) 1.06
Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur J Pharmacol (1998) 1.06
Fusion of a cleavable signal peptide to the ectodomain of neutral endopeptidase (EC 3.4.24.11) results in the secretion of an active enzyme in COS-1 cells. J Biol Chem (1989) 1.05
A highly sensitive fluorometric assay for "enkephalinase," a neutral metalloendopeptidase that releases tyrosine-glycine-glycine from enkephalins. Anal Biochem (1984) 1.04
Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and of mu and delta opioid receptors in rat brain. Proc Natl Acad Sci U S A (1986) 1.04
Investigation of zinc-binding affinities of Moloney murine leukemia virus nucleocapsid protein and its related zinc finger and modified peptides. Biopolymers (1991) 1.04
The prosequence of thermolysin acts as an intramolecular chaperone when expressed in trans with the mature sequence in Escherichia coli. J Mol Biol (1999) 1.03
Zinc binding to the HIV-1 nucleocapsid protein: a thermodynamic investigation by fluorescence spectroscopy. Biochemistry (1996) 1.03
Geometry of the antitumor drug ditercalinium bisintercalated into d(CpGpCpG)2 by 1H NMR. Proc Natl Acad Sci U S A (1987) 1.03
Evidence that both arginine 102 and arginine 747 are involved in substrate binding to neutral endopeptidase (EC 3.4.24.11). J Biol Chem (1991) 1.02
In vitro evidence for the interaction of tRNA(3)(Lys) with U3 during the first strand transfer of HIV-1 reverse transcription. Nucleic Acids Res (2000) 1.02
NMR structure of the HIV-1 regulatory protein Vpr in H2O/trifluoroethanol. Comparison with the Vpr N-terminal (1-51) and C-terminal (52-96) domains. Eur J Biochem (2002) 1.01
Radioimmunoassay of methionine- and leucine-enkephalins in regions of rat brain and comparison with endorphins estimated by a radioreceptor assay. J Neurochem (1978) 1.01
Measurement of the expected DNA lengthening caused by mono-and bisintercalating drugs using electron microscopy. Biopolymers (1978) 1.01
Complete differentiation between enkephalinase and angiotensin-converting enzyme inhibition by retro-thiorphan. Proc Natl Acad Sci U S A (1983) 1.01
A model of PSI dimerization: destabilization of the C278-G303 stem-loop by the nucleocapsid protein (NCp10) of MoMuLV. Biochemistry (1996) 1.01
Cooperative exosite-dependent cleavage of synaptobrevin by tetanus toxin light chain. J Biol Chem (1997) 1.00
Binding of the HIV-1 nucleocapsid protein to the primer tRNA(3Lys), in vitro, is essentially not specific. J Biol Chem (1995) 1.00
Differential interactions of the growth factor receptor-bound protein 2 N-SH3 domain with son of sevenless and dynamin. Potential role in the Ras-dependent signaling pathway. J Biol Chem (1998) 1.00
Synthesis of 11H-pyridocarbazoles and derivatives. Comparison of their DNA binding and antitumor activity with those of 6H- and 7H-pyridocarbazoles. J Med Chem (1986) 0.99
Enkephalin dipeptidyl carboxypeptidase (enkephalinase) activity: selective radioassay, properties, and regional distribution in human brain. J Neurochem (1982) 0.99
Effects of kelatorphan and other peptidase inhibitors on the in vitro and in vivo release of methionine-enkephalin-like material from the rat spinal cord. J Pharmacol Exp Ther (1986) 0.98
Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol (2001) 0.97
Solution structure of GAP SH3 domain by 1H NMR and spatial arrangement of essential Ras signaling-involved sequence. EMBO J (1994) 0.97
Characterization of Glu350 as a critical residue involved in the N-terminal amine binding site of aminopeptidase N (EC 3.4.11.2): insights into its mechanism of action. Biochemistry (1998) 0.96
Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels. Eur J Pharmacol (1998) 0.96
Direct activation of protein phosphatase-2A0 by HIV-1 encoded protein complex NCp7:vpr. FEBS Lett (1997) 0.96